Genitourinary Cancers | Specialty

Expert Discusses Success of Stereotactic Radiation in RCC

May 12th 2017

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation for patients with renal cell carcinoma and highlights ongoing trials examining the modality.

Dr. McDermott on the Role of VEGF Targeted Therapy in RCC

May 11th 2017

David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma.

Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder Cancer

May 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

May 9th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

FDA Approves Avelumab for Bladder Cancer

May 9th 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

May 5th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Expert Stresses Significance of Genetic Differences in Kidney Cancer

May 4th 2017

W. Marston Linehan, MD, discusses the landscape of kidney cancer, current clinical trials, and hope for the future of immunotherapy in this disease.

Dr. Apolo on Avelumab for Metastatic Urothelial Carcinoma

May 4th 2017

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.

Dr. Nanus on Ongoing Studies in the Neoadjuvant Setting for RCC

May 3rd 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses ongoing studies in the neoadjuvant setting for patients with renal cell carcinoma (RCC).

Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer

May 2nd 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

FDA Approves Durvalumab for Bladder Cancer

May 1st 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer

April 28th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Dr. Choueiri on Existing Therapies for Kidney Cancer

April 26th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the current therapies for patients with kidney cancer.

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Combination Therapies for Advanced Bladder Cancer

April 22nd 2017

Highlights of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Use of Immune Checkpoint Inhibitors for Bladder Cancer

April 22nd 2017

Future Treatment Options for Advanced Bladder Cancer

April 22nd 2017

Durvalumab for Treatment of Advanced Bladder Cancer

April 22nd 2017

Immune Checkpoint Inhibitors for Advanced Bladder Cancer

April 22nd 2017